UK markets close in 1 hour 40 minutes

Hutchison China MediTech Limited (HCM)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
36.31-0.25 (-0.68%)
As of 9:50AM EDT. Market open.

Hutchison China MediTech Limited

Cheung Kong Center
48th Floor 2 Queen's Road
Hong Kong
852 2128 1188

Full-time employees1,280

Key executives

NameTitlePayExercisedYear born
Mr. Chi Keung To B.Sc., M.B.A., BSc, ACGI, MBAExec. Chairman80kN/A1952
Mr. Christian Hogg B.Sc., M.B.A., BSc, MBACEO & Exec. Director1.41MN/A1966
Mr. Johnny Cheng C.A., BEc, CACFO & Exec. Director788.96kN/A1967
Dr. Wei-Guo Su B.Sc., Ph.D.Chief Scientific Officer, Exec. VP & Exec. Director1.21MN/A1957
Ms. Edith Shih C.S., CGP, FCS, M.A., P.E., BSE, MA, EdM, SolicitoCompany Sec. & Non-Exec. Director70kN/A1952
Mr. Mark LeeSr. VP of Corp. Fin. & Devel.N/AN/A1977
Mr. Charles NixonGroup Gen. CounselN/AN/AN/A
Mr. Andrew ShihSr. VP of HR - Organization & Leadership Devel.N/AN/AN/A
Dr. May WangSr. VP of Bus. Devel. & Strategic AlliancesN/AN/A1963
Mr. Hong ChenChief Commercial Officer - China, GM - Hutchison Sinopharm & GM - Hutchison HealthcareN/AN/A1970
Amounts are as of 31 December 2020, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


HUTCHMED (China) Limited discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases worldwide. It operates in two segments, Oncology/Immunology and Other Ventures. It manufactures, distributes, markets, and sells prescription and over-the-counter pharmaceutical, and consumer health products. The company develops Savolitinib, an inhibitor for non-small cell lung cancer (NSCLC), papillary and clear cell renal cell carcinoma, colorectal cancer (CRC), and gastric cancer (GC); and Fruquintinib, an inhibitor for CRC, breast cancer, GC, endometrial cancer (EMC), NSCLC, hepatocellular carcinoma, and gastrointestinal and solid tumors. It also develops Surufatinib, an inhibitor for neuroendocrine tumors (NET), pancreatic NET, non-pancreatic NET, biliary tract cancer, sarcoma, neuroendocrine neoplasm, esophageal cancer, small cell lung cancer, GC, thyroid cancer, EMC, NSCLC, and solid tumors; HMPL-523, an inhibitor for indolent non-Hodgkin's lymphoma (NHL), B-cell malignancies, and immune thrombocytopenic purpura; and HMPL-689 for indolent non-Hodgkin's, follicular, marginal zone, mantle cell, diffuse large B cell, chronic lymphocytic leukemia/small lymphocytic, and Hodgkin's lymphoma. The company develops HMPL-453, an inhibitor for intrahepatic cholangiocarcinoma; HMPL-306, an inhibitor for hematological malignancies, gliomas, and solid tumors; HMPL-295 for solid tumors; and HMPL-813 and HMPL-309 EGFR inhibitors. It has collaboration agreements with AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, BeiGene, Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics (Suzhou) Co., Inc., Genor Biopharma Co. Ltd., Shanghai Junshi Biosciences Co. Ltd., and Epizyme, Inc. The company was formerly known as Hutchison China MediTech Limited and changed its name to HUTCHMED (China) Limited in May 2021. HUTCHMED (China) Limited was incorporated in 2000 and is headquartered in Central, Hong Kong.

Corporate governance

Hutchison China MediTech Limited’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.